Amphastar Pharmaceuticals Current Ratio 2012-2026 | AMPH
Amphastar Pharmaceuticals current ratio from 2012 to 2026. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Amphastar Pharmaceuticals Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2026-03-31 | $0.63B | $0.16B | 3.85 |
| 2025-12-31 | $0.64B | $0.16B | 4.02 |
| 2025-09-30 | $0.64B | $0.21B | 3.12 |
| 2025-06-30 | $0.58B | $0.18B | 3.29 |
| 2025-03-31 | $0.59B | $0.20B | 2.95 |
| 2024-12-31 | $0.53B | $0.17B | 3.07 |
| 2024-09-30 | $0.55B | $0.16B | 3.43 |
| 2024-06-30 | $0.48B | $0.14B | 3.52 |
| 2024-03-31 | $0.56B | $0.26B | 2.18 |
| 2023-12-31 | $0.49B | $0.23B | 2.17 |
| 2023-09-30 | $0.54B | $0.26B | 2.11 |
| 2023-06-30 | $0.39B | $0.25B | 1.53 |
| 2023-03-31 | $0.41B | $0.11B | 3.86 |
| 2022-12-31 | $0.38B | $0.10B | 3.99 |
| 2022-09-30 | $0.38B | $0.10B | 3.76 |
| 2022-06-30 | $0.38B | $0.10B | 3.64 |
| 2022-03-31 | $0.36B | $0.11B | 3.19 |
| 2021-12-31 | $0.32B | $0.10B | 3.06 |
| 2021-09-30 | $0.30B | $0.10B | 3.10 |
| 2021-06-30 | $0.31B | $0.13B | 2.50 |
| 2021-03-31 | $0.30B | $0.13B | 2.36 |
| 2020-12-31 | $0.28B | $0.11B | 2.49 |
| 2020-09-30 | $0.28B | $0.10B | 2.86 |
| 2020-06-30 | $0.27B | $0.09B | 2.86 |
| 2020-03-31 | $0.25B | $0.08B | 2.96 |
| 2019-12-31 | $0.26B | $0.09B | 2.84 |
| 2019-09-30 | $0.27B | $0.09B | 3.11 |
| 2019-06-30 | $0.28B | $0.10B | 2.81 |
| 2019-03-31 | $0.23B | $0.11B | 2.06 |
| 2018-12-31 | $0.22B | $0.11B | 2.06 |
| 2018-09-30 | $0.20B | $0.10B | 2.02 |
| 2018-06-30 | $0.17B | $0.09B | 1.94 |
| 2018-03-31 | $0.17B | $0.07B | 2.40 |
| 2017-12-31 | $0.19B | $0.07B | 2.80 |
| 2017-09-30 | $0.18B | $0.06B | 3.08 |
| 2017-06-30 | $0.19B | $0.06B | 3.04 |
| 2017-03-31 | $0.19B | $0.07B | 2.63 |
| 2016-12-31 | $0.18B | $0.06B | 3.04 |
| 2016-09-30 | $0.19B | $0.06B | 3.13 |
| 2016-06-30 | $0.18B | $0.07B | 2.76 |
| 2016-03-31 | $0.17B | $0.07B | 2.67 |
| 2015-12-31 | $0.18B | $0.06B | 2.93 |
| 2015-09-30 | $0.20B | $0.07B | 2.82 |
| 2015-06-30 | $0.20B | $0.07B | 2.94 |
| 2015-03-31 | $0.20B | $0.07B | 2.81 |
| 2014-12-31 | $0.20B | $0.06B | 3.16 |
| 2014-09-30 | $0.22B | $0.06B | 3.41 |
| 2014-06-30 | $0.21B | $0.06B | 3.81 |
| 2014-03-31 | $0.18B | $0.07B | 2.44 |
| 2013-12-31 | $0.17B | $0.07B | 2.65 |
| 2013-09-30 | $0.00B | 0.00 | |
| 2013-06-30 | $0.00B | 0.00 | |
| 2013-03-31 | $0.00B | 0.00 | |
| 2012-12-31 | $0.17B | $0.06B | 2.76 |
| 2012-09-30 | $0.00B | 0.00 | |
| 2012-06-30 | $0.00B | 0.00 | |
| 2012-03-31 | $0.00B | 0.00 | |
| 2011-12-31 | $0.00B | 0.00 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.924B | $0.720B |
| Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |